INTRODUCTION: Anaemia is a common problem in patients with cancer who receive chemotherapy and is normally associated with a negative impact on patients' quality of life (QOL), poor cancer control and diminished survival. In clinical trials, recombinant human erythropoietin has been shown to correct and prevent anaemia, decrease the need for blood transfusions and improve cancer patients' QOL. METHODS: A retrospective study followed lung cancer patients who received first-line chemotherapy in our hospital in 1998 and in 2005. The incidence of anaemia was analysed, as was the impact of incorporating erythropoietin into the treatment. RESULTS: The incidence of anaemia was 68% (69% of which reported asthenia) in 1998 vs. 54% (60% with asthenia) in 2005. The comparison of anaemia rates (1998 vs. 2005) were grade 1 (16% vs. 32%), grade 2 (36% vs. 16%), grade 3 (16% vs. 5%) and grade 4 (none). Treatment for anaemia included transfusion 52%, intravenous iron 5% and epoetin 4% in 1998. In 2005 anaemia was treated with transfusion 9%, intravenous iron 41%, and epoetin 49%. Median survival (1998 vs. 2005) was 242 days [95% confidence interval (CI) 217-329) vs. 356 days (95% CI 322-382). CONCLUSIONS: Erythropoietin is a valid alternative for cancer patients with anaemia undergoing chemotherapy. It can possibly avoid the need for transfusions without negatively impacting survival.
INTRODUCTION:Anaemia is a common problem in patients with cancer who receive chemotherapy and is normally associated with a negative impact on patients' quality of life (QOL), poor cancer control and diminished survival. In clinical trials, recombinant humanerythropoietin has been shown to correct and prevent anaemia, decrease the need for blood transfusions and improve cancerpatients' QOL. METHODS: A retrospective study followed lung cancerpatients who received first-line chemotherapy in our hospital in 1998 and in 2005. The incidence of anaemia was analysed, as was the impact of incorporating erythropoietin into the treatment. RESULTS: The incidence of anaemia was 68% (69% of which reported asthenia) in 1998 vs. 54% (60% with asthenia) in 2005. The comparison of anaemia rates (1998 vs. 2005) were grade 1 (16% vs. 32%), grade 2 (36% vs. 16%), grade 3 (16% vs. 5%) and grade 4 (none). Treatment for anaemia included transfusion 52%, intravenous iron 5% and epoetin 4% in 1998. In 2005 anaemia was treated with transfusion 9%, intravenous iron 41%, and epoetin 49%. Median survival (1998 vs. 2005) was 242 days [95% confidence interval (CI) 217-329) vs. 356 days (95% CI 322-382). CONCLUSIONS:Erythropoietin is a valid alternative for cancerpatients with anaemia undergoing chemotherapy. It can possibly avoid the need for transfusions without negatively impacting survival.
Authors: Javier de Castro; Amalio Ordóñez; Dolores Isla; Alfredo Sánchez; Antonio Arrivi; José Luis Manzano; Manuel González Barón Journal: Cancer Chemother Pharmacol Date: 2006-07-28 Impact factor: 3.333
Authors: C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran Journal: Eur J Cancer Date: 2006-12-19 Impact factor: 9.162
Authors: Peter Vaupel; Jürgen Dunst; Andreas Engert; Joachim Fandrey; Petra Feyer; Mathias Freund; Wolfgang Jelkmann Journal: Onkologie Date: 2005-03-31
Authors: Gerassimos A Pangalis; Marina P Siakantaris; Maria K Angelopoulou; Theodoros P Vassilakopoulos; Maria N Dimopoulou; Marie-Christine Kyrtsonis; Konstantinos Konstantopoulos; Panayiotis Tsaftaridis; George A Vaiopoulos; Flora N Kontopidou Journal: Haematologica Date: 2002-05 Impact factor: 9.941
Authors: Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506